SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants.
Ontology highlight
ABSTRACT: Coronavirus 19 Disease (COVID-19) originating in the province of Wuhan, China in 2019, is caused by the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), whose infection in humans causes mild or severe clinical manifestations that mainly affect the respiratory system. So far, the COVID-19 has caused more than 2 million deaths worldwide. SARS-CoV-2 contains the Spike (S) glycoprotein on its surface, which is the main target for current vaccine development because antibodies directed against this protein can neutralize the infection. Companies and academic institutions have developed vaccines based on the S glycoprotein, as well as its antigenic domains and epitopes, which have been proven effective in generating neutralizing antibodies. However, the emergence of new SARS-Co
SUBMITTER: Martinez-Flores D
PROVIDER: S-EPMC8311925 | biostudies-literature | 2021
REPOSITORIES: biostudies-literature
ACCESS DATA